Your Partner in Neuroscience Drug Discovery

Your Partner in Neuroscience Drug Discovery

AXOSIM PARTNERS WITH PRECLINICAL SCIENTISTS TO SOLVE ADVANCED PROBLEMS IN THE DRUG DISCOVERY AND DEVELOPMENT PROCESSES

Selection of drug candidates is a difficult and imperfect process requiring predictive modeling. Too often, animal and other preclinical models are not predictive in humans. Without this knowledge, selection of the wrong candidate can result in losses of money, time, and resources. We aim to help navigate this path by providing rodent and human predictive in vitro modeling.

Our industry leading biomimetic platforms enable us to work with our clients and partners to apply predictive data assisting in identification of better drug candidates, earlier, and more accurately and efficiently.

HUMAN DATA, FASTER.

HUMAN DATA,

By providing predictive data we aim to help toxicologists and discovery scientists make informed decisions as they advance from high-throughput in vitro assays to IND-enabling studies. Our services help researchers throughout the drug development process in both a sponsored (fee-for-service) and partnered research design.

NerveSim®

How it Works

AxoSim's NerveSim® platform facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.

BrainSim®

How it Works

BrainSim® is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.

News & Publications

AxoSim 2022 Year in Review Featured Image

AxoSim 2022 Year in Review

News and Blog

AxoSim’s 2022 Year in Review publication highlights company achievements, technology highlights and goals moving into 2023.  View  the full report featuring Q&As […]

Read More

Our Partners & Funders

At AxoSim, we frequently like to remind ourselves of our mission- empowering advancements in human neuroscience. We take a minute- away from the lab bench, protocols, schedules, budgets, and pipettes- and remember, that at the end of all the research, is people. Human beings that we know and love that are fighting daily battles with neurological diseases.

Megan Morris, MSE